The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Autor: Rodríguez-Abreu, D., Cobo, M., García-Román, S., Viteri-Ramírez, S., Jordana-Ariza, N., García-Peláez, B., Reguart, N., Aguilar, A., Codony-Servat, J., Drozdowskyj, A., Molina-Vila, M.A., d'Hondt, E., Rosell, R.

Publikováno v: In Lung Cancer February 2022 164:8-13

EP08.02-032 High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid

Autor: Garzón Ibañez, M., Aguado Esteban, C., García-Peláez, B., Gimenez Capitán, A., Vives Usano, M., Berrocal, L., Valarezo, J., Aguilar, A., Garcia Casabal, F., Viteri Ramirez, S., Cabrera, C., Gonzalez Cao, M., Rosell, R., Molina-Vila, M.A., de las Casas, C.M.

Publikováno v: In Journal of Thoracic Oncology September 2022 17(9) Supplement:S412-S412

1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial

Autor: Garcia Campelo, M.R., Felip, E., Besse, B., Cobo Dols, M., Quoix, E., Madroszyk Flandin, A-C., Cappuzzo, F., Denis, F., Hilgers, W., Romano, G., Debieuvre, D., Galetta, D., Baldini, E., Viteri Ramirez, S., Duc Phan, M., Schuette, W., Zer, A., Vasseur, B., Dziadziuszko, R., Giaccone, G.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1020-S1020

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform.

Autor: Giménez-Capitán A; Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain., Bracht J; Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain.; Universitat Autónoma de Barcelona, Barcelona, Spain., García JJ; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain., Jordana-Ariza N; Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain., García B; Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain., Garzón M; Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain., Mayo-de-Las-Casas C; Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain., Viteri-Ramirez S; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain., Martinez-Bueno A; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain., Aguilar A; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain., Sullivan IG; Medical Oncology Service, Hospital de Sant Pau, Barcelona, Spain., Johnson E; NanoString Technologies, Seattle, WA., Huang CY; NanoString Technologies, Seattle, WA., Gerlach JL; NanoString Technologies, Seattle, WA., Warren S; NanoString Technologies, Seattle, WA., Beechem JM; NanoString Technologies, Seattle, WA., Teixidó C; Department of Pathology, Thoracic Oncology Unit, Hospital Clínic, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain., Rosell R; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain.; Cancer Biology and Precision Medicine Program, Catalán Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain., Reguart N; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Medical Oncology, Thoracic Oncology Unit, Hospital Clínic, Barcelona, Spain., Molina-Vila MA; Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain.

Publikováno v: Clinical chemistry [Clin Chem] 2021 Mar 01; Vol. 67 (3), pp. 554-563.